These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 8380519)

  • 1. Role of dopamine autoxidation, hydroxyl radical generation, and calcium overload in underlying mechanisms involved in MPTP-induced parkinsonism.
    Chiueh CC; Miyake H; Peng MT
    Adv Neurol; 1993; 60():251-8. PubMed ID: 8380519
    [No Abstract]   [Full Text] [Related]  

  • 2. Metabolic aspects of the behavior of MPTP and some analogues.
    Tipton KF; McCrodden JM; Sullivan JP
    Adv Neurol; 1993; 60():186-93. PubMed ID: 8420134
    [No Abstract]   [Full Text] [Related]  

  • 3. Biochemical mechanisms underlying MPTP-induced and idiopathic parkinsonism. New vistas.
    Singer TP; Ramsay RR; Sonsalla PK; Nicklas WJ; Heikkila RE
    Adv Neurol; 1993; 60():300-5. PubMed ID: 8380523
    [No Abstract]   [Full Text] [Related]  

  • 4. [Experimental model of Parkinson disease: mechanisms and anatomo- pathological characteristics of MPTP neurotoxicity].
    Herrero MT; Luquín MR; Obeso JA
    Arch Neurobiol (Madr); 1992; 55(4):175-82. PubMed ID: 1417423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early-stage loss of dopamine uptake-site binding in MPTP-treated monkeys.
    Graybiel AM; Moratalla R; Quinn B; DeLanney LE; Irwin I; Langston JW
    Adv Neurol; 1993; 60():34-9. PubMed ID: 8420148
    [No Abstract]   [Full Text] [Related]  

  • 6. D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity.
    Muralikrishnan D; Samantaray S; Mohanakumar KP
    Synapse; 2003 Oct; 50(1):7-13. PubMed ID: 12872288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transferrin receptor regulation in Parkinson's disease and MPTP-treated mice.
    Mash DC; Sanchez-Ramos J; Weiner WJ
    Adv Neurol; 1993; 60():133-9. PubMed ID: 8420130
    [No Abstract]   [Full Text] [Related]  

  • 8. Ro 16-6491: a new reversible and highly selective MAO-B inhibitor protects mice from the dopaminergic neurotoxicity of MPTP.
    Da Prada M; Kettler R; Keller HH; Bonetti EP; Imhof R
    Adv Neurol; 1987; 45():175-8. PubMed ID: 2881442
    [No Abstract]   [Full Text] [Related]  

  • 9. Changes of tyrosine hydroxylase in parkinsonian brains and in the brains of MPTP-treated mice.
    Nagatsu T
    Adv Neurol; 1990; 53():207-14. PubMed ID: 1978515
    [No Abstract]   [Full Text] [Related]  

  • 10. Degeneration of dopaminergic neurons and free radicals. Possible participation of levodopa.
    Ogawa N; Edamatsu R; Mizukawa K; Asanuma M; Kohno M; Mori A
    Adv Neurol; 1993; 60():242-50. PubMed ID: 8380518
    [No Abstract]   [Full Text] [Related]  

  • 11. Trichloroethylene: Parkinsonism and complex 1 mitochondrial neurotoxicity.
    Gash DM; Rutland K; Hudson NL; Sullivan PG; Bing G; Cass WA; Pandya JD; Liu M; Choi DY; Hunter RL; Gerhardt GA; Smith CD; Slevin JT; Prince TS
    Ann Neurol; 2008 Feb; 63(2):184-92. PubMed ID: 18157908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The possible role of iron in the etiopathology of Parkinson's disease.
    Youdim MB; Ben-Shachar D; Riederer P
    Mov Disord; 1993; 8(1):1-12. PubMed ID: 8419792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The specific vulnerability of the substantia nigra to MPTP is related to the presence of transition metals.
    Poirier J; Donaldson J; Barbeau A
    Biochem Biophys Res Commun; 1985 Apr; 128(1):25-33. PubMed ID: 2985073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Search for the cause of Parkinson's disease].
    Langston JW
    Arch Neurobiol (Madr); 1991; 54(6):264-71. PubMed ID: 1811457
    [No Abstract]   [Full Text] [Related]  

  • 15. Age-related severity of dopaminergic neurodegeneration to MPTP neurotoxicity causes motor dysfunction in C57BL/6 mice.
    Ohashi S; Mori A; Kurihara N; Mitsumoto Y; Nakai M
    Neurosci Lett; 2006 Jun; 401(1-2):183-7. PubMed ID: 16581184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced hydroxyl radical generation by 2'-methyl analog of MPTP: suppression by clorgyline and deprenyl.
    Chiueh CC; Huang SJ; Murphy DL
    Synapse; 1992 Aug; 11(4):346-8. PubMed ID: 1323883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The neurotoxicity of iron and nitric oxide. Relevance to the etiology of Parkinson's disease.
    Youdim MB; Ben-Shachar D; Eshel G; Finberg JP; Riederer P
    Adv Neurol; 1993; 60():259-66. PubMed ID: 8380520
    [No Abstract]   [Full Text] [Related]  

  • 18. Pathogenesis and animal studies of Parkinson's disease.
    Oertel WH; Kupsch A
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):323-32. PubMed ID: 8507901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A beam-walking apparatus to assess behavioural impairments in MPTP-treated mice: pharmacological validation with R-(-)-deprenyl.
    Quinn LP; Perren MJ; Brackenborough KT; Woodhams PL; Vidgeon-Hart M; Chapman H; Pangalos MN; Upton N; Virley DJ
    J Neurosci Methods; 2007 Aug; 164(1):43-9. PubMed ID: 17498809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic bovine proline-rich-polypeptides generate hydroxyl radicals and fail to protect dopaminergic neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity in mice.
    Knaryan VH; Samantaray S; Varghese M; Srinivasan A; Galoyan AA; Mohanakumar KP
    Neuropeptides; 2006 Aug; 40(4):291-8. PubMed ID: 16712929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.